Targeted radio-nuclide therapy of skeletal metastases

2013 ◽  
Vol 39 (1) ◽  
pp. 18-26 ◽  
Author(s):  
Oliver Sartor ◽  
Peter Hoskin ◽  
Øyvind S. Bruland
Keyword(s):  
Skeletal Metastases ◽  
Radio Nuclide ◽  
Nuclide Therapy

Systemic Radionuclide Palliative Therapy for Metastatic Carcinoma with Strontium 89

1997 ◽  
Vol 10 (5) ◽  
pp. 352-360
Author(s):  
Frank J. Papatheofanis ◽  
Paul A. Windisch ◽  
Karl A. Matuszewski
Keyword(s):  
Bone Pain ◽  
External Beam Radiotherapy ◽  
Palliative Therapy ◽  
Metastatic Carcinoma ◽  
Treatment Modalities ◽  
Skeletal Metastases ◽  
Newly Diagnosed ◽  
Skeletal System ◽  
Radio Nuclide ◽  
Nuclide Therapy

Metastatic carcinoma is the most common neoplasm involving the skeletal system. It is estimated that 30% to 70% of newly diagnosed cancer patients develop osseous metastases, causing intractable bone pain. A variety of treatments have been used to control bone pain associated with skeletal metastases, including analgesics, cytotoxic chemotherapy, external beam radiotherapy and systemic radio-nuclide therapy. Strontium 89 (89Sr) is a systemic radionuclide and calcium analog that has been extensively used for pain control in advanced skeletal metastatic disease. Strontium 89 offers advantages over other treatment modalities, including repeated treatments if necessary, less bone marrow suppression and toxicity and potential for cost effectiveness.

1096: Whole Body Optical Imaging of Skeletal Metastases: Pathogenic Relationship with Bone Turnover and Therapeutic Rationale

2004 ◽  
Vol 171 (4S) ◽  
pp. 289-289
Author(s):  
Gabri van der Pluijm ◽  
Antoinette Wetterwald ◽  
George N. Thalmann ◽  
Guus Lycklama A. Nijeholt ◽  
Rob Pelger ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Optical Imaging ◽  
Whole Body ◽  
Skeletal Metastases

Bisphosphonates in Breast Cancer Patients with Skeletal Metastases

1994 ◽  
Vol 8 (1) ◽  
pp. 153-163 ◽  
Author(s):  
Charles L. Shapiro
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Skeletal Metastases ◽  
Breast Cancer Patients

Scintigraphy with 99m Tc-Phosphonate and 67Gallium in Patients Suspected of Primary Bone Tumors

1982 ◽  
Vol 21 (04) ◽  
pp. 136-139 ◽  
Author(s):  
C.-J. Edeling
Keyword(s):  
Soft Tissue ◽  
Bone Scintigraphy ◽  
Primary Tumor ◽  
Bone Tumors ◽  
Whole Body ◽  
Skeletal Metastases ◽  
Malignant Bone Tumors ◽  
67Ga Scintigraphy ◽  
Primary Bone Tumors ◽  
Primary Bone

Whole-body scintigraphy with both 99mTc-phosphonate and 67Ga was performed on 92 patients suspected of primary bone tumors. In 46 patients with primary malignant bone tumors, scintigraphy with 99mTc-phosphonate disclosed the primary tumor in 44 cases and skeletal metastases in 11, and 67Ga scintigraphy detected the primary tumor in 43 cases, skeletal metastases in 6 cases and soft-tissue metastases in 8 cases. In 25 patients with secondary malignant bone tumors, bone scintigraphy visualized a single lesion in 10 cases and several lesions in 15 cases, and 67Ga scintigraphy detected the primary tumor in 17 cases, skeletal metastases in 17 cases and soft-tissue metastases in 9 cases. In 21 patients with benign bone disease positive uptake of 99mTc-phosphonate was recognized in 19 cases and uptake of 67Ga in 17 cases. It is concluded that bone scintigraphy should be used in patients suspected of primary bone tumors. If malignancy is suspected, 67Ga scintigraphy should be performed in addition.

Computed Tomography of Skeletal Metastases with Contrast

2020 ◽  
Author(s):  
Keyword(s):  
Computed Tomography ◽  
Skeletal Metastases

scholarly journals HGK promotes metastatic dissemination in prostate cancer

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Sara Garcia-Garcia ◽  
Maria Rodrigo-Faus ◽  
Noelia Fonseca ◽  
Sara Manzano ◽  
Balázs Győrffy ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prognostic Biomarker ◽  
Skeletal Metastases ◽  
Primary Tumors ◽  
Prostate Tumorigenesis ◽  
Actin Organization ◽  
Multi Stage ◽  
Adhesion Stability ◽  
Therapeutic Alternatives ◽  
Cell Dissemination

AbstractMetastasis is the process of cancer cell dissemination from primary tumors to different organs being the bone the preferred site for metastatic homing of prostate cancer (PCa) cells. Prostate tumorigenesis is a multi-stage process that ultimately tends to advance to become metastatic PCa. Once PCa patients develop skeletal metastases, they eventually succumb to the disease. Therefore, it is imperative to identify essential molecular drivers of this process to develop new therapeutic alternatives for the treatment of this devastating disease. Here, we have identified MAP4K4 as a relevant gene for metastasis in PCa. Our work shows that genetic deletion of MAP4K4 or pharmacological inhibition of its encoded kinase, HGK, inhibits metastatic PCa cells migration and clonogenic properties. Hence, MAP4K4 might promote metastasis and tumor growth. Mechanistically, our results indicate that HGK depleted cells exhibit profound differences in F-actin organization, increasing cell spreading and focal adhesion stability. Additionally, HGK depleted cells fails to respond to TNF-α stimulation and chemoattractant action. Moreover, here we show that HGK upregulation in PCa samples from TCGA and other databases correlates with a poor prognosis of the disease. Hence, we suggest that it could be used as prognostic biomarker to predict the appearance of an aggressive phenotype of PCa tumors and ultimately, the appearance of metastasis. In summary, our results highlight an essential role for HGK in the dissemination of PCa cells and its potential use as prognostic biomarker.

scholarly journals An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases

2021 ◽  
Author(s):  
Jad S. Husseini ◽  
Bárbara Juarez Amorim ◽  
Angel Torrado-Carvajal ◽  
Vinay Prabhu ◽  
David Groshar ◽  
...  
Keyword(s):  
Expert Opinion ◽  
Skeletal Metastases ◽  
International Expert

scholarly journals [177Lu]Lu-DOTA-ZOL bone pain palliation in patients with skeletal metastases from various cancers: efficacy and safety results

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Madhav Prasad Yadav ◽  
Sanjana Ballal ◽  
Marian Meckel ◽  
Frank Roesch ◽  
Chandrasekhar Bal
Keyword(s):  
Overall Survival ◽  
Pain Assessment ◽  
Bone Pain ◽  
Performance Status ◽  
Response Assessment ◽  
Assessment Criteria ◽  
Skeletal Metastases ◽  
Efficacy And Safety ◽  
Pain Palliation ◽  
Global Pain

Abstract Background [177Lu]Lu-DOTA-ZOL has shown promising results from the dosimetry and preclinical aspects, but data on its role in the clinical efficacy are limited. The objective of this study is to evaluate the efficacy and safety of [177Lu]Lu-DOTA-ZOL as a bone pain palliation agent in patients experiencing pain due to skeletal metastases from various cancers. Methods In total, 40 patients experiencing bone pain due to skeletal metastases were enrolled in this study. The patients were treated with a mean cumulative dose of 2.1 ± 0.6 GBq (1.3–2.7 GBq) [177Lu]Lu-DOTA-ZOL in a median follow-up duration of 10 months (IQR 8–14 months). The primary outcome endpoint was response assessment according to the visual analogue score (VAS). Secondary endpoints included analgesic score (AS), global pain assessment score, Eastern Cooperative Oncology Group Assessment performance status (ECOG), Karnofsky performance status, overall survival, and safety assessment by the National Cancer Institute’s Common Toxicity Criteria V5.0. Results In total, 40 patients (15 males and 25 females) with a mean age of 46.6 ± 15.08 years (range 24–78 years) were treated with either 1 (N = 15) or 2 (N = 25) cycles of [177Lu]Lu-DOTA-ZOL. According to the VAS response assessment criteria, complete, partial, and minimal responses were observed in 11 (27.5%), 20 (50%), and 5 patients (12.5%), respectively with an overall response rate of 90%. Global pain assessment criteria revealed complete, partial, minimal, and no response in 2 (5%), 25 (62.5%), 9 (22.5%), and 4 (10%) patients, respectively. Twenty-eight patients died and the estimated median overall survival was 13 months (95% CI 10–14 months). A significant improvement was observed in the VAS, AS, and ECOG status when compared to baseline. None of the patients experienced grade III/IV haematological, kidney, or hepatotoxicity due to [177Lu]Lu-DOTA-ZOL therapy. Conclusion [177Lu]Lu-DOTA-ZOL shows promising results and is an effective radiopharmaceutical in the treatment of bone pain due to skeletal metastases from various cancers.

Sign in / Sign up

Export Citation Format

Share Document